Highlights of This Issue 2009
FROM THE EDITOR-IN-CHIEF

2011 The Patient Impact Factor

THE BEST OF MCT–10 YEARS

2012 Shining the Light on Aurora-A Kinase as a Drug Target in Pancreatic Cancer David J. Bearss

2013 First Report of Functional Chk1 siRNA Studies Applied to Drug Discovery Zehan Chen

2015 The Discovery and Development of SU14813, a Next-Generation Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Human Malignancies Dana Hu-Lowe, Nicoletta Brega, and Shem Patyna

2016 PI3K Inhibitors for Cancer Treatment: Five Years of Preclinical and Clinical Research after BEZ235 Sauveur-Michel Maira

2017 Discovering and Developing PI3 Kinase Inhibitors for Cancer: Rapid Progress through Academic-Biotech-Pharma Interactions Florence I. Raynaud and Paul Workman

2019 The Discovery of Lapatinib (GW572016) David Rusnak and Tona M. Gilmer

2020 Methylation Profiling of Lung Cancer: A Decade of Progress Shinich Toyoooka and Adi F. Gazdar

2021 MicroRNAs in Cancer Pharmacology and Therapeutics: Exploiting a Natural Synergy between ‘-omic’ and Hypothesis-Driven Research John N. Weinstein

2022 Development of the First Generation c-Met Kinase Inhibitors: Beginning of a Path to a New Treatment for Cancer Xueyan Wang, Gerald McMahon, and Kenneth E. Lipson

2024 Proof of Principle for Crizotinib in Anaplastic Lymphoma Kinase-Positive Malignancies Was Achieved in ALK-Positive Nonclinical Models James G. Christensen

2025 Lapatinib: Functional Genomics Study Leads to Insights into Mechanism of Action Tona M. Gilmer

2026 Bench to Bedside and Back Again: Personalizing Treatment for Patients with GIST Andrew K. Godwin

2028 The Importance of PK/PD Data–Key Biological Answers Needed to Evaluate the Success of Potential Cancer Therapeutics Rakesh Kumar and Benjamin Suttle

2029 Bortezomib: Understanding the Mechanism of Action Bilal Piperdi, Yi-He Ling, Leonard Liebes, Franco Muggia, and Roman Perez-Soler

2030 Starting with the ABCs: Akt in Breast Cancer Kip A. West and Phillip A. Dennis

2032 Cell Line Models Identify Different Sensitivity of Mutant Forms of c-KIT to Kinase Inhibitory Drugs and Predict the Response of Patients to Therapy Leonie K. Ashman

2034 Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma Teru Hideshima, Paul G. Richardson, and Kenneth C. Anderson

REVIEW

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma Teru Hideshima, Paul G. Richardson, and Kenneth C. Anderson
THERAPEUTIC DISCOVERY

2043 Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Kruppel-like Factor 5 Expression by Ultrahigh-Throughput Screening
Agnieszka B. Bialkowska, Melissa Crisp, Thomas Bannister, Yuanjun He, Sarwat Chowdhury, Stephan Schurer, Peter Chase, Timothy Spicer, Franck Madoux, Chenlu Tian, Peter Hodder, Daniel Zaharevitz, and Vincent W. Yang

2052 Discovery and Evaluation of Inhibitors of Human Ceramidase
Jeremiah M. Draper, Zuping Xia, Ryan A. Smith, Yan Zhuang, Wenxue Wang, and Charles D. Smith

2062 Targeting the Intracellular MUC1 C-terminal Domain Inhibits Proliferation and Estrogen Receptor Transcriptional Activity in Lung Adenocarcinoma Cells
Carolyn M. Klinge, Brandie N. Radde, Yoannis Mrbet-Fernandez, Yun Teng, Margarita M. Ivanova, Sabra M. Abner, and Alexandra L. Martin

2072 A6 Peptide Activates CD44 Adhesive Activity, Induces FAK and MEK Phosphorylation, and Inhibits the Migration and Metastasis of CD44-Expressing Cells
Randolph S. Piotrowicz, Bassam B. Damaj, Mohamed Hachicha, Francesca Incardona, Stephen B. Howell, and Malcolm Finlayson

2083 Digitoxin-Induced Cytotoxicity in Cancer Cells Is Mediated through Distinct Kinase and Interferon Signaling Networks
Ioannis Prassas, George S. Karagiannis, Iliar Batruch, Apostolos Dimitromanolakis, Alessandro Dati, and Eleftherios P. Diamandis

PRECLINICAL DEVELOPMENT

2094 Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways
Laura S. Angelo, Ji Yuan Wu, Feng Meng, Michael Sun, Scott Kopetz, Ian E. McCutcheon, John M. Slopis, and Razelle Kurzrock

2104 Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells
Daina Z. Ewton, Jing Hu, Maria Vilenchik, Xiaobing Deng, Kin-chun Luk, Ann Polonskaia, Ann F. Hoffman, Karen Zipf, John F. Boylan, and Eileen A. Friedman

2115 The Aurora Kinase Inhibitor CCT37690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

2124 Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells

2135 Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment

2146 3,5-Bis(2,4-Difluorobenzylidene)-4-piperidone, a Novel Compound That Affects Pancreatic Cancer Growth and Angiogenesis
Dharmalingam Subramaniam, Nathan G. Nichols, Animesh Dhar, Shahid Umar, Vibhudutta Awasthi, Danny R. Welch, Roy A. Jensen, and Shrikant Anant

2157 Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer
Johannes Taeger, Christian Moser, Claus Hellerbrand, Maria E. Mycielska, Gabriel Glockzin, Hans J. Schlitt, Edward K. Geissler, Oliver Stolzting, and Sven A. Lang
MOLECULAR MEDICINE IN PRACTICE

Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization
Timothy Meier, Mark Uhlik, Sudhakar Chintharlapalli, Michele Dowless, Robert Van Horn, Julie Stewart, Wayne Blosser, James Cook, Debra Young, Xiang Ye, Glenn Evans, Kelly Credille, Darryl Ballard, Lysiane Huber, Andrew Capen, Marcio Chedid, Robert Ilaria, Jr., Michele C. Smith, and Louis Stancato

Antitumoral Effects of Calcitriol in Basal Cell Carcinomas Involve Inhibition of Hedgehog Signaling and Induction of Vitamin D Receptor Signaling and Differentiation
Anja Uhmann, Hannah Niemann, Béatrice Lammering, Cornelia Henkel, Ina Heß, Frauke Nitzki, Anne Fritsch, Nicole Prüfer, Albert Rosenberger, Christian Dullin, Anke Schraepfer, Julia Reifenberger, Stefan Schweyer, Torsten Pietsch, Frank Strutz, Walter Schulz-Schaefeer, and Heidi Hahn

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
Genshi Zhao, Wei-ying Li, Daohong Chen, James R. Henry, Hong-Yu Li, Zhaogen Chen, Mohammad Zia-Ebrahimi, Laura Bloom, Yan Zhai, Karen Huss, Sheng-bin Peng, and Denis J. McCann

Correction: Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

ABOUT THE COVER

Met kinase homology model with its inhibitor, SU11271, docked in the ATP binding site. The cover image was selected from an article previously published in Molecular Cancer Therapeutics, which was chosen in celebration of the 10th anniversary of the journal. For details, see the commentary by Wang and colleagues on page 2022.
Molecular Cancer Therapeutics

10 (11)


Updated version  Access the most recent version of this article at: http://mct.aacrjournals.org/content/10/11

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.